Biogen Inc. has demonstrated various significant
activities in the biotech market. They have initiated numerous advanced studies including
BRAVE and Phase 3 trial for
Friedreich Ataxia children's treatment. A large number of asset management companies, including
North Growth Management Ltd and Fifth Third Bancorp, have increased their shares in the company significantly. The firm also plans to present their financial results for Q1 of 2025 by May 1st. Amid such activities, the company is also considering a
bid in the Sage Therapeutics merger developments. Biogen's Q1 earnings are expected to reveal key metrics against estimates. Importantly, they have entered into a
partnership with City Therapeutics on a US$1 billion RNAi therapy deal. Furthermore, analysts have demonstrated mixed sentiments about Biogen with some maintaining a neutral rating while others got bullish. Significantly, Biogen received FDA Fast Track Designation for its Investigational Tau-Targeting Therapy BIIB080 for Alzheimer’s disease treatment.
Biogen BIIB News Analytics from Wed, 04 Sep 2024 07:00:00 GMT to Sat, 21 Jun 2025 09:55:11 GMT -
Rating 5
- Innovation 2
- Information 7
- Rumor 3
